Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-985; Location: LEVEL 3, HALL B3; P3 | "At baseline (randomization), 156/285 patients (54.7%) received CRT (hydroxyurea [HU], n = 109; interferon, n = 38; ruxolitinib, n = 7; other, n = 2), and 129 received PHL only. Analysis showed 41.7% of baseline CRT-treated PHL-dependent PV patients reduced or discontinued CRT during rusfertide exposure while maintaining hematocrit <45%, suggesting rusfertide may reduce PHL and/or CRT burden in patients with PV who have poorly controlled hematocrit."
Clinical • P3 data • Retrospective data • Oncology • Polycythemia Vera
|
|
Andrew T Kuykendall MD 1; Francesca Palandri 2; Gregory S Vosganian 3; Aniket Bankar 4; Naveen Pemmaraju 5; Kristen M Pettit 6; Valentín García-Gutiérrez 7; Alessandro Lucchesi 8; Jiri Mayer 9; Harinder Gill 10; Antonin Hlusi 11; Daniel Sasca 12; Joseph M Scandura 13; David M Ross 14; Maria Laura Fox 15; Alessandro Maria Vannucchi 16; Steffen Koschmieder 17; Jean-Jacques Kiladjian 18; Phillip Dinh 3; Jie Xiao 3; Joseph Shatzel 19
|